Targeting anticancer immunity in oral cancer: Drugs, products, and nanoparticles

Identifying the prognosis implication, immunotherapy response prediction value, and potential targeted compound inhibitors of integrin subunit α3 (ITGA3) in human cancers

“…Moreover, as vital surface adhesion receptors mediate interactions between the ECM, the regulation of integrins in the ECM may be closely related to the above processes [ 4 ]. In addition, previous studies have found that Tregs and MDSCs could help tumors avoid the response to immunotherapy and promote tumor immunosuppression [ [47] , [48] , [49] , [50] ]. Activated TGF-β could lead to the formation of EMT and CAFs, and simultaneously cause the dysregulation of genes in the ECM, which ultimately affects the efficacy of immunotherapy [ 51 , 52 ].…”

Anticancer potential of thiocolchicoside and lauric acid loaded chitosan nanogel against oral cancer cell lines: a comprehensive study

“…Head and neck squamous cell carcinoma is the sixth leading cancer worldwide 1 . At the same time, Oral Squamous Cell Carcinoma (OSCC) is the most commonly occurring malignancy among head and neck malignancies, and finding effective treatment and patient management has always been a significant priority 2 . In 2020, Oral cancer was the 11th most common malignancy in men and the 18th most common malignancy in women worldwide.…”

“…Recently, targeted therapies, particularly Ferroptosis, have gained significant attention as potential treatment strategies 6 . Nanoparticles-loaded natural products and their adjuvants can induce redox reactions and immunogenic effects in oral cancer cells and suppress immunosuppressive mechanisms in the tumour microenvironment 2 .…”